• profile
  • History
  • Business Model
    • Portfolio Model
    • Licensing
  • Management Team
  • Board of Directors
  • Consultative Committee
  • Professional Affiliations

• products
  • Nimotuzumab
    • Science
    • Safety Profile
    • Clinical Trials
    • Consortium
    • Licensee Links
  • AeroLEF®
    • Science
    • Variable Dosing
    • Clinical Trials
  • CYT387
    • Science
    • Clinical Trials
  • CYT997
    • Science
    • Clinical Trials
  • Clinical Trials
  • Request Medical Info

• investors
  • Financial Reports
  • Regulatory Filings
  • Stock Information
  • Press Releases
  • Calendar of Events
  • Presentations
  • Corporate Governance
  • Investor Contacts
  • Email Sign-up
  • F.A.Q.

• patients
  • Nimotuzumab
    • Patients - Canada
    • Patients - USA
    • Patients - Worldwide
  • CYT387
  • CYT997
  • AeroLEF®

• physicians
  • Nimotuzumab
  • CYT387
  • CYT997
  • AeroLEF®

• contact
  • Investor Contacts
  • Licensing Contact
  • Clinical Contact

Regulatory Filings

Annual Information Forms (AIFs)

	Year Ended June 30, 2009 (English - on Form 20F)
	Year Ended June 30, 2008 (English - on Form 20F)
	Year Ended June 30, 2007 (English)
	Year Ended June 30, 2006 (English)
	Year Ended June 30, 2005 Amended (English)
	Year Ended June 30, 2004 (English)
	Year Ended June 30, 2003 (English)
	Year Ended June 30, 2002 (English)
	Year Ended June 31, 2001 (English)

Management Proxy / Information Circular (BC, ON - Form 30, QC)

	October 9, 2009
	October 21, 2008
	October 23, 2007
	October 10, 2006
	September 28, 2005
	November 17, 2004
	November 5, 2003
	November 6, 2002

Final Prospectus

	February 14, 2006 - Supplement (English)
	September 23, 2004 - Short Form (English)
	February 13, 2004 - Long Form (English)
	May 31, 2002 - Long Form (English)
	May 31, 2002 - Long Form (French)
	May 31, 2002 - UK Wrap for Final Prospectus

View other YM BioSciences public documents at www.sedar.com.